Episode 48: Ginkgo Bioworks

In this episode of Petri Dish Perspectives, we unpack how Ginkgo Bioworks set out to industrialize biology. From its origins at MIT to building one of the most ambitious synthetic biology platforms in the world, we explore how the company positioned itself not as a traditional biotech, but as a “organism engineering foundry.”

We break down Ginkgo’s unique business model, partnering with companies across pharma, agriculture, and consumer goods and how it generates value through cell programming, automation, and massive biological datasets. We also examine the company’s rapid rise, its high-profile SPAC debut, and the intense scrutiny that followed.

Along the way, we dive into the science behind synthetic biology, the challenges of scaling engineered organisms, and the big question: can biology truly become an engineering discipline?

If you want to understand the future of programmable biology and whether Ginkgo’s platform-first approach can reshape entire industries, this episode is for you.

🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!

https://linktr.ee/maneadkhin

#Biotech #SyntheticBiology #GinkgoBioworks #Biotechnology #Bioengineering #DrugDevelopment #LifeSciences #Bioeconomy #Startup #SPAC #Innovation #PetriDishPerspectives

Transcript

Hello and welcome to Petri Dish Perspectives, the podcast where we geek out about science and the companies shaping the future of healthcare. I’m your host, Manead, and I’m a PhD scientist by training, biotech storyteller by choice. With every new episode released on Thursday, my goal is to deliver digestible pieces of information on healthcare companies under 30 mins. 

If you follow the world of "TechBio," there is one name that evokes either radical optimism or deep skepticism: Ginkgo Bioworks. They don’t call themselves a pharmaceutical company. They call themselves "The Organism Company." Their pitch is simple but world-altering: if you can program a computer with 0s and 1s, why can’t you program a cell with A, T, C, and G? Today, we are diving into the story of a company that tried to turn biology into a manufacturing platform—and how, as of 2026, they are desperately trying to reinvent themselves as the "Robotics and AI" backbone of the entire industry.

Quick disclaimer, I give full credit to the original articles cited in the references in the transcript!

Grab a coffee or tea, settle in, and let’s jump in!

The Scrappy Founding: The $200,000 "Garage" in Boston

Most billion-dollar biotechs start with a Nobel Prize and a $50 million Series A. Ginkgo started with five people and a collection of eBay logins.

In 2008, the economy was collapsing, but at MIT, a legendary computer scientist named Tom Knight was convinced that the next great programming language wouldn't be Java—it would be DNA. He teamed up with four of his brightest PhD students: Jason Kelly, Reshma Shetty, Barry Canton, and Austin Che. They didn't want to work for Big Pharma. They wanted to be the infrastructure for everyone else. But because they launched during the Great Recession, venture capital was non-existent. So they did something unheard of in biotech: they bootstrapped.

• The eBay Lab: They pooled roughly $200,000 in personal savings and grant money. To build their first lab, they spent nights scouring eBay for "hand-me-down" mass spectrometers and liquid handlers.
• 27 Drydock Ave: They set up shop in a gritty industrial building in South Boston—27 Drydock Avenue. It wasn't a sleek research park; it was an area dominated by seafood wholesalers.
• The Y Combinator Pivot: For six years, they lived on government grants from DARPA and the NSF. Then, in 2014, they became the first-ever biotech accepted into Y Combinator. This was the turning point. It taught them to stop talking like academics and start talking like a platform company. They weren't selling a drug; they were selling "Cell Programming as a Service."

Rise to Prominence: The $17.5B SPAC and the Pandemic Pivot

The years 2020 and 2021 were the "Ginkgo Supercycle." When the pandemic hit, Ginkgo launched Concentric by Ginkgo, a massive biosecurity and COVID-19 testing platform. Suddenly, a company that was engineering yeast for perfumes was running the nation’s school testing programs and monitoring airports for new variants.

This revenue surge, combined with the "SPAC mania" of 2021, led Ginkgo to go public via Soaring Eagle Acquisition Corp. at a staggering $17.5 billion valuation. They took the ticker DNA—the same one Genentech used back in the day. They were the poster child for "Synthetic Biology," promising that their platform would eventually take a "royalty" on every biological product in the world.

The Acquisition Machine: Swallowing the Competition

Armed with billions from their IPO, Ginkgo went on a buying spree to expand their horizontal reach:

• Zymergen (2022): In a "rescue" acquisition, Ginkgo bought their biggest rival for $300 million after Zymergen's own product strategy collapsed.
• Patch Biosciences (2024): They integrated Patch’s AI-driven sequence design to bolster their genetic medicine offerings.
• StrideBio (2023): This gave them the tools to engineer AAV capsids for gene therapy, moving them deeper into the high-margin world of Biopharma.

The Big Three: Platforms of 2026

As of March 2026, Ginkgo has moved away from just "programming cells" and is now selling the infrastructure of science:

1. Reconfigurable Automation Carts (RACs): The "Lab-in-a-Box" This is their biggest strategic shift. Instead of just doing the work for you, Ginkgo now sells the robots. These "RACs" allow other companies to build their own automated labs using Ginkgo’s proprietary software. They are moving toward a "Life Science Tools" model, similar to Thermo Fisher.

2. Ginkgo Datapoints: The Bio-AI Data Provider In 2024, they launched "Datapoints." Because AI models like GPT-5 need massive amounts of clean biological data to learn, Ginkgo is now acting as a "data factory." They run thousands of parallel experiments just to feed the results into AI training sets for Big Pharma.

3. The OpenAI "Lab-in-the-Loop" Collaboration Ginkgo recently unveiled a landmark project with OpenAI where a reasoning model (GPT-5) was given "hands" in the Boston foundry. The AI designed experiments, the robots executed them 24/7, and the AI learned from the data in real-time—achieving a 40% improvement in protein synthesis over human-designed methods.

The Platform in Action: Chronic Diseases and RNA

Critics often ask: "What have they actually built?" By 2026, the answer is in the pipelines of the world's biggest drugmakers. Ginkgo doesn't "own" these drugs; they are the high-tech factory that designs them.

1. The Novo Nordisk "GLP-1" Engine The biggest partnership in their history is with Novo Nordisk. As the world demands more Ozempic and Wegovy, the bottleneck is manufacturing. Ginkgo is using its "Foundry" to re-engineer the expression systems for these chronic disease medications. They are essentially rewriting the "software" inside the yeast cells to make them pump out peptides faster, cheaper, and more reliably than traditional methods.

2. The Pfizer RNA Codebase While everyone knows Pfizer for the COVID vaccine, Ginkgo is helping them build the next generation of RNA. In their $331 million collaboration, Ginkgo isn't just looking for one vaccine; they are using high-throughput screening to find "RNA constructs" with better stability. Imagine an mRNA drug that doesn't need to be frozen or a treatment that lasts twice as long in the body. Ginkgo’s robots are testing thousands of these variations simultaneously to find the "winners."

Criticism and Challenges: The "Theranos 2.0" Shadow

Ginkgo’s journey has not been without controversy. In 2021, short-seller Scorpion Capital released a scathing report calling the company a "colossal scam" and "Theranos 2.0," alleging that their revenue was mostly "circular" (money coming from their own startups).

While Ginkgo survived the report, the financial reality of 2025 and 2026 has been tough. Revenue from biosecurity has plummeted, and the company reported a 25% decline in total revenue in late 2025. Their stock price, which once flirted with $15, has spent much of the last year under $7. Critics argue that "programming biology" is still much harder and more expensive than Ginkgo’s glossy PowerPoint slides suggest.

People Who Made Their Mark

While Jason Kelly is the face of the company, many insiders point to Shyam Sankar as the man who is defining Ginkgo’s 2026 strategy.

Shyam isn't a biologist—he is the Chief Technology Officer of Palantir. As the chair of Ginkgo's board, he has brought a "defense-grade" software philosophy to the company.

• The "Forward Deployed" Mindset: At Palantir, Shyam pioneered the idea of sending engineers directly into the field to solve messy problems. He has pushed Ginkgo to do the same—turning the "Foundry" into a modular system where scientists can "deploy" code to cells just like software.
• The "Mobilize" Vision: In early 2026, Sankar published his book Mobilize, arguing that Western democracies need to reindustrialize to compete with China. He views Ginkgo not just as a biotech company, but as a critical part of the American Industrial Base. To Shyam, biological manufacturing is a matter of national security.
• The Architect of the Pivot: It was under Sankar’s chairmanship that Ginkgo made its most aggressive move: divesting its COVID-era biosecurity business (Concentric) in February 2026 to focus 100% on the Autonomous Lab. He is the one betting that Ginkgo's future isn't in "doing science" for people, but in providing the "Bio-OS" that everyone else runs on.

Lessons and Strategic Direction: The Infrastructure Pivot

The "Ginkgo Lesson" is about platform vs. product. For years, Ginkgo tried to do everything for everyone. But by 2026, they have realized that being a "service provider" is low-margin and high-friction.

The Strategic Direction: They are pivoting to a "Hybrid Tools and AI" company. They are divesting their biosecurity business (Concentric) to focus entirely on the Autonomous Lab.

• The Lesson: In a gold rush, don't just mine for gold (drugs); sell the shovels (robots and data).
• The Direction: They want to become the "Amazon Web Services of Biology." If you want to run a biological experiment in 2027, Ginkgo wants you to do it on their hardware, using their data, via their cloud.

What’s next? 2026: The "Cloud Lab" and the OpenAI Breakthrough

March 2026 has been a whirlwind for the company. They just launched the Ginkgo Cloud Lab, which is essentially "AWS for Biology."

• EstiMate: They introduced an AI agent that allows any researcher in the world to type a protocol in plain English. The AI calculates the price and tells the robots in Boston to start pipetting.
• The GPT-5 "Hands": In a landmark study with OpenAI, Ginkgo demonstrated that a GPT-5 model could autonomously design a protein, send the instructions to Ginkgo’s robots, and optimize the result 40% better than human scientists. It was the first time an AI had "closed the loop" in a physical lab without human intervention.

Outro: The Long Game

Ginkgo Bioworks is a bet on the next 50 years. They are currently in the "trough of disillusionment," facing massive losses and a skeptical market. But if their vision of "Autonomous Labs" holds true, they may yet become the operating system for the living world.

This has been Petri Dish Perspectives. I’m Manead. Thanks for listening. See you next Thursday. Good bye.

References

1. https://sunpharma.com/usa/ 
2. www.wikipedia.org
3. https://www.fiercebiotech.com/ 
4. https://finance.yahoo.com/ 
5. https://endpoints.news/